Get notified when HCWB files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Material Weakness (worsened) — The 10-Q/A discloses two material weaknesses (long-lived asset impairment + warrant accounting) vs. one in the original 10-Q, reflecting a broader control breakdown.
  • Restatement (new) — The 10-Q/A restates Q1 2026 EPS due to failure to apply the two-class method for warrant participating securities under ASC 260.
  • Going Concern (new) — Filing states that conditions raise substantial doubt about the company's ability to continue as a going concern. The same disclosure appeared in the baseline filing.
NASDAQ: HCWB HCW Biologics Inc. 10-Q/A

HCWB restates Q1 2026 EPS on warrant accounting error; two material weaknesses now disclosed

Filed August 14, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 14, 2026 · ~2 min read

Key Financials

SEC XBRL

Period financials are unchanged from the original 10-Q (same period end Mar 31, 2026). This amendment updates disclosure only — see the diff below.

Key Changes

  • high

    The 10-Q/A discloses two material weaknesses in internal controls (long-lived asset impairment + warrant accounting) vs. one in the original 10-Q, reflecting a broader breakdown in technical accounting review controls for complex warrant and financing transactions.

    Controls & Procedures verify on EDGAR →
  • high

    Q1 2026 EPS restated from $0.37 to $1.39 per share after applying the two-class method for participating warrants; the error allocated $728k of net income to warrant holders that the original filing attributed to common stockholders. Weighted-average shares drop from 5.4M to 904k.

    Notes: EPS Calculation view on EDGAR →
  • medium

    The amendment corrects February 2026 financing terms: 412,882 units at $3.633 per unit (not 2.5M units at $0.6055), and repriced 503,402 existing warrants from $14.46 to $3.633 (not 3.0M warrants from $2.41). Gross proceeds remain $1.5M.

    MD&A: Financing Terms verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (ZEO 10-Q) is open in full — no account needed.

Partner

Trade HCWB commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov

Figures/quotes linked to EDGAR · Narrative written by AI · Aug 17, 2026 · How we verify